AstraZeneca Pharma India Limited, a prominent player in the pharmaceutical sector, has reported a strong financial performance for the first quarter, marking a significant turnaround from the previous year.

Financial Highlights

The company's total income from operations soared to Rs. 5,375.50 million, representing a substantial 35.8% increase from Rs. 3,958.70 million in the corresponding quarter of the previous year. This impressive growth in revenue underscores the company's strong market position and effective business strategies.

In a remarkable turnaround, AstraZeneca Pharma India posted a net profit after tax of Rs. 558.30 million, compared to a loss of Rs. 117.90 million in the same quarter last year. This shift from loss to profit demonstrates the company's improved operational efficiency and cost management.

The earnings per share (EPS) saw a dramatic improvement, reaching Rs. 22.33, up from a loss per share of Rs. 4.72 in the previous year. This significant increase in EPS reflects the company's enhanced profitability and potential value for shareholders.

Key Financial Metrics

Operational Changes

During the quarter, AstraZeneca Pharma India made a strategic decision to cease operations at its manufacturing site and commence plant decommissioning. As a result, the plant and machinery related to the manufacturing site have been fully depreciated. This move is likely part of the company's efforts to optimize its operations and improve overall efficiency.

Corporate Governance

The financial results were reviewed and recommended by the Audit Committee of the Board and subsequently approved by the Board of Directors at their respective meetings held on August 14. The statutory auditors of the company have carried out a limited review of the financial results, ensuring compliance with regulatory requirements and maintaining transparency for stakeholders.

Annual General Meeting

AstraZeneca Pharma India Limited held its 46th Annual General Meeting (AGM) on August 14 through video conferencing. All resolutions mentioned in the AGM notice were duly passed by the company's members with the requisite majority, as confirmed by the scrutinizer's report dated August 18.

AstraZeneca Pharma India's strong Q1 performance, coupled with strategic operational changes, positions the company favorably in the competitive pharmaceutical landscape. Investors and industry observers will likely keep a close watch on how these positive results and operational shifts translate into long-term growth and sustainability for the company.

AstraZeneca Pharma India Limited, a leading science-led biopharmaceutical company, has announced impressive financial results for the first quarter, demonstrating strong growth across its diverse therapy areas.

Financial Highlights

• Revenue: Increased by 36% to ₹5,263.10 million, up from ₹3,875.20 million in the same quarter of the previous year
• Net Profit: Returned to profitability with ₹558.30 million, compared to a loss of ₹117.90 million in the same quarter last year
• EBITDA: More than doubled to ₹811.00 million from ₹380.00 million year-over-year
• EBITDA Margin: Expanded significantly to 15.40% from 9.82% in the previous year's quarter

Therapy-wise Performance

The company's oncology segment showed remarkable growth, while the biopharmaceuticals segment experienced a slight decline. The rare disease segment, although small, doubled its revenue compared to the previous year.

Key Milestones and Approvals

AstraZeneca Pharma India has made significant strides in expanding its portfolio and strengthening its market position:

1. Received approval for Osimertinib tablets for an additional indication in non-small cell lung cancer (NSCLC) treatment.
2. Gained approval for trastuzumab deruxtecan for additional indications in HER2-low and HER2-ultralow metastatic breast cancer.
3. Obtained approval for Osimertinib as a monotherapy for locally advanced, unresectable (stage III) NSCLC.
4. Secured approval for Benralizumab as an add-on treatment for adult patients with relapsing or refractory eosinophilic granulomatosis with polyangiitis (EGPA).

Management Commentary

Bhavana Agrawal, Chief Financial Officer & Director, commented on the results: "Our strong Q1 performance reflects the power of science-led innovation combined with disciplined execution. Each regulatory milestone brings us closer to transforming outcomes for patients living with chronic diseases."

Praveen Rao Akkinepally, Country President & Managing Director, added: "Delivering consistent growth across therapy areas reaffirms the strength of our Growth Through Innovation strategy and the passion of our teams to help more patients."

Recognition and Awards

AstraZeneca Pharma India's commitment to excellence has been acknowledged through various recognitions:

• OPPI Medical Excellence Award for Medical Affairs, Regulatory Excellence, and Clinical Trials
• 1st Place in the SAS Customer Recognition Awards for innovative use of Real-World Data in clinical trials
• Featured by Fortune India as a leading multinational transforming healthcare in India

As AstraZeneca Pharma India Limited celebrates its 45th year in India, the company continues to focus on expanding its portfolio, strengthening partnerships, and ensuring that breakthrough medicines reach patients who need them most. With a workforce of over 600 employees across the country, AstraZeneca remains committed to delivering innovative science and excellence in development and commercialization of life-changing medicines.